All News

Found 387 articles

• Veterinary Artificial Insemination Market: Rise in Demand for High Quality Milk Products is Expected to Drive the Global Market

  6/27/2022

  Wilmington, Delaware, United States: Artificial insemination is a technique, in which semen with live sperm is collected and introduced into female reproductive tract at proper time with help of equipment.

• IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility

  6/22/2022

  IMV achieves predetermined milestone to access the remaining $US10 Million under its Debt Facility with Horizon.

• 

  "The Ultimate Riddle" – An Expert's Perspective on The Immunology Field

  6/9/2022

  BioSpace interviewed Marianne Stanford, Ph.D., who shared her thoughts on the immunology field and the career path of an immunologist.

• Tracheostomy Products Market Size, Share, Growth, Trends | Report 2022-2030

  5/23/2022

  The volume of surgical operations has increased with the rising incidence of chronic respiratory illnesses, such as Cardiovascular Diseases (CVDs), diabetes, respiratory diseases, cancer, or other respiratory injuries.

• IMV Inc. to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating in person at the H.C. Wainwright Global Investment Conference, which will be held in person and virtually May 23-26, 2022,

• CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

  5/13/2022

  CytoDyn Inc. announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Company’s Scientific Board of Advisors.

• IMV Inc. Announces First Quarter 2022 Financial and Operational Results

  5/13/2022

  IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the first quarter ended March 31, 2022.

• Strategikon Pharma Announces the Release of Clinical Maestro® SOURCE 3.0

  5/11/2022

  Strategikon Pharma announced today the release of Clinical Maestro® SOURCE version 3.0.

• IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022

  5/6/2022

  IMV Inc. today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company’s 2022 first quarter financial and operational results.

• Endoscopy Operative Devices Market Size to Hit US$ 20.7 Bn by 2030

  5/3/2022

  The global Endoscopy Operative Devices market size is expected to hit around US$ 20.7 billion by 2030 from valued at US$ 10.0 billion in 2020 with a CAGR of 6.1% during forecast period 2021 to 2030.

• Biomanufacturing Talent Market Dynamics:- ‘The rise of a talent bull market’

  5/2/2022

  With the industry focused on vaccines and virus-associated therapies, particularly within mRNA vaccines and therapeutics, the pandemic increased the demand for staff to support the operations scale up across biomanufacturing.

• Multiplex Detection Immunoassays Market Size to Surpass US$ 3.5 BN by 2030

  5/2/2022

  The global multiplex detection immunoassays market size is projected to surpass around US$ 3.5 billion by 2030 and is anticipated to grow at a CAGR of 7.3% during forecast period 2021 to 2030.

• IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting

  4/28/2022

  IMV Inc. announced the Company’s lead compound, maveropepimut-S, will be showcased in two presentations in breast and ovarian cancer at the 2022 American Society of Clinical Oncology Annual Meeting.

• Cancer Immunotherapy Market Size to Worth Around US$ 130.6 BN by 2030

  4/26/2022

  According to Report, the global cancer immunotherapy market size is expected to be worth around US$ 130.6 billion by 2030 and is anticipated to grow at a CAGR of 10.6% from 2021 to 2030.

• IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting

  4/8/2022

  IMV Inc. announced safety and preliminary efficacy data of the combination of the Company’s lead immunotherapy candidate, maveropepimut-S, with pembrolizumab from a Phase 2 basket study of patients with advanced, metastatic bladder cancer.

• Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022

  4/8/2022

  Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, is presenting data on the activity of the company’s tumor-derived immunotherapies in glioblastoma and other solid tumors at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, La.

• IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting

  4/6/2022

  IMV Inc. today announced the Company will present a poster at IMMUNOLOGY™ 2022, the annual meeting of the American Association of Immunologists (AAI).

• IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results

  3/17/2022

  IMV Inc. today announced its financial and operational results, and provided an update for the fourth quarter and year ended December 31, 2021.

• IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022

  3/10/2022

  IMV Inc. today announced that it will hold a conference call and webcast on Thursday, March 17, 2022, at 8:00 a.m. ET to discuss the company’s 2021 fourth quarter and fiscal year-end financial and operational results.

• IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

  3/9/2022

  IMV Inc. today announced that the Company will showcase its DPX delivery technology in two presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.